Vaxcyte, Inc.
PCVX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.21 | -0.38 | 1.27 | -0.52 |
| FCF Yield | -3.17% | -2.30% | -3.77% | -1.41% |
| EV / EBITDA | -22.45 | -26.00 | -27.65 | -185.24 |
| Quality | ||||
| ROIC | -8.14% | -7.17% | -5.50% | -4.80% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.67 | 0.73 | 1.18 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -52.83% | 47.34% | -36.48% | -43.16% |
| Safety | ||||
| Net Debt / EBITDA | 0.94 | 1.37 | 1.48 | 6.02 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -566.70 | 0.00 | 0.00 |